CYP3A5 Genotype Has No Impact on Plasma Trough Concentrations of Lopinavir and Ritonavir in HIV‐infected Subjects

CYP3A5 genotype has no impact on the trough plasma concentrations of lopinavir and ritonavir in human immunodeficiency virus (HIV)‐infected individuals on stable highly active antiretroviral therapy (HAART). This is ascribed to a drug interaction, such that ritonavir by inhibiting CYP3A activity, may occlude the pharmacokinetic consequences of functional polymorphisms in the CYP3A5 gene. In the clinical setting, where lopinavir and ritonavir are always combined, CYP3A5 genotype is of no consequence on the trough plasma concentrations of these drugs.

[1]  M. Schechter,et al.  Limited Penetration of Lopinavir and Ritonavir in the Genital Tract of Men Infected with HIV-1 in Brazil , 2006, Therapeutic drug monitoring.

[2]  Jaran Eriksen,et al.  CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population , 2006, Pharmacogenetics and genomics.

[3]  G. Suarez-Kurtz.  Pharmacogenetics in the Brazilian Population , 2010, Front. Pharmacol..

[4]  J. Beijnen,et al.  Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. , 2005, British journal of clinical pharmacology.

[5]  David B. Witonsky,et al.  CYP3A variation and the evolution of salt-sensitivity variants. , 2004, American journal of human genetics.

[6]  Dale J. Kempf,et al.  ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease , 1998, Antimicrobial Agents and Chemotherapy.

[7]  Jan-Gowth Chang,et al.  Polymorphism analysis of CYP3A5 in myeloid leukemia. , 2002, Oncology reports.

[8]  P. Neuvonen,et al.  Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. , 2006, Basic & clinical pharmacology & toxicology.

[9]  S. D. Pena,et al.  Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. , 2007, Pharmacogenomics.

[10]  W. Haefeli,et al.  CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir , 2007, Clinical pharmacology and therapeutics.

[11]  C. Solas,et al.  Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients , 2003, Antimicrobial Agents and Chemotherapy.

[12]  C. Ernest,et al.  Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.